Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kamada stock | $7.19

Own Kamada stock in just a few minutes.

Fact checked

Kamada Ltd is a drug manufacturers-specialty & generic business based in the US. Kamada shares (KMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Kamada employs 429 staff and has a trailing 12-month revenue of around USD$133.8 million.

How to buy shares in Kamada

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Kamada. Find the stock by name or ticker symbol: KMDA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kamada reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.19, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kamada, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Kamada. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kamada share price

Use our graph to track the performance of KMDA stocks over time.

Kamada shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$7.19
52-week rangeUSD$4.4 - USD$13.33
50-day moving average USD$6.6041
200-day moving average USD$8.1668
Wall St. target priceUSD$11
PE ratio 13.75
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.48

Buy Kamada shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kamada stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kamada price performance over time

Historical closes compared with the close of $7.19 from 2021-01-11

1 week (2021-01-08) 8.77%
1 month (2020-12-15) 10.62%
3 months (2020-10-15) -9.45%
6 months (2020-07-15) -18.11%
1 year (2020-01-15) 11.30%
2 years (2019-01-15) 34.90%
3 years (2018-01-12) 27.26%
5 years (2016-01-15) 81.57%

Is Kamada under- or over-valued?

Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Kamada's P/E ratio

Kamada's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Kamada shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Kamada's PEG ratio

Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Kamada's EBITDA

Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$25.9 million.

The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.

Kamada financials

Revenue TTM USD$133.8 million
Operating margin TTM 16.5%
Gross profit TTM USD$49.7 million
Return on assets TTM 7.6%
Return on equity TTM 13.6%
Profit margin 15.6%
Book value $3.878
Market capitalisation USD$290.9 million

TTM: trailing 12 months

Shorting Kamada shares

There are currently 572,349 Kamada shares held short by investors – that's known as Kamada's "short interest". This figure is 3.8% up from 551,400 last month.

There are a few different ways that this level of interest in shorting Kamada shares can be evaluated.

Kamada's "short interest ratio" (SIR)

Kamada's "short interest ratio" (SIR) is the quantity of Kamada shares currently shorted divided by the average quantity of Kamada shares traded daily (recently around 131574.48275862). Kamada's SIR currently stands at 4.35. In other words for every 100,000 Kamada shares traded daily on the market, roughly 4350 shares are currently held short.

However Kamada's short interest can also be evaluated against the total number of Kamada shares, or, against the total number of tradable Kamada shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kamada's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Kamada shares in existence, roughly 10 shares are currently held short) or 0.0198% of the tradable shares (for every 100,000 tradable Kamada shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kamada.

Find out more about how you can short Kamada stock.

Kamada share dividends

We're not expecting Kamada to pay a dividend over the next 12 months.

Kamada share price volatility

Over the last 12 months, Kamada's shares have ranged in value from as little as $4.4 up to $13.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.4198. This would suggest that Kamada's shares are less volatile than average (for this exchange).

Kamada overview

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company's products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent that are in Phase II stage; and Inhaled AAT for AAT deficiency, which is in Phase II and III stages. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was founded in 1990 and is headquartered in Rehovot, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site